Publications by authors named "Nisar A Baig"

Claim this Profile
C
Correction to: Size fraction of hazardous particulate matter governing the respiratory deposition and inhalation risk in the highly polluted city Delhi.
Ananya Das, Nisar Ali Baig, Mohammad Yawar, Arun Kumar, Gazala Habib

Environ Sci Pollut Res Int· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Size fraction of hazardous particulate matter governing the respiratory deposition and inhalation risk in the highly polluted city Delhi.
Ananya Das, Nisar Ali Baig, Mohammad Yawar, Arun Kumar, Gazala Habib

Environ Sci Pollut Res Int· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab interference in flow cytometric anti-granulocyte antibody testing can be overcome using non-human blocking antibodies.
Nisar A Baig, Brian A Dukek, Deborah K Falbo, Laurie L Wakefield, Margaret A DiGuardo

Vox Sang· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells.
Clive S Zent, Ronald P Taylor, Margaret A Lindorfer, Paul V Beum, Betsy LaPlant, Nisar A Baig

Am J Hematol· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia.
Nisar A Baig, Ronald P Taylor, Margaret A Lindorfer, Amy K Church, Betsy R LaPlant

J Immunol· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement.
Nisar A Baig, Ronald P Taylor, Margaret A Lindorfer, Amy K Church, Betsy R Laplant

Leuk Lymphoma· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis